Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main focus: Next-generation cell therapies for the treatment of cancer
Company stage: Pre-clinical
Diseases (gene editing): Multiple myeloma (MM), Acute myeloid leukaemia (AML), ovarian cancer, non-small cell lung cancer (NSCLC), breast cancer
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: Galway, Republic of Ireland
Gene-editing partnerships: Intellia Therapeutics
ONK Therapeutics develops next-generation natural killer (NK) cell-based therapies for the treatment of cancer. The company tries to deploy multiple different knock-outs of different genes using CRISPR-Cas9 in its chimeric antigen receptor NK (CAR-NK) products. While the company is still conducting pre-clinical studies, it has disclosed multiple different haematological and solid tumour types that it will initially target. The company has established a collaboration with Intellia Therapeutics, which gives ONK Therapeutics non-exclusive rights to the CRISPR-Cas9 system and lipid nanoparticle (LNP) delivery technologies.